SCHEMBL22988846

SCHEMBL22988846

Cc1nc(NC(=O)N2CCC(C)(C)C2=O)ccc1Cc1c[nH]c2ncccc12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 3/20 0.45
▸ KIT P10721 3/20 0.45
▸ PDGFRA P16234 2/20 0.45
▸ GPR84 Q9NQS5 1/20 0.43
▸ CYP3A4 P08684 4/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ HCRTR1 O43613 2/20 0.41
▸ HCRTR2 O43614 2/20 0.41
▸ MTNR1A P48039 1/20 0.40
▸ DRD4 P21917 6/20 0.38
▸ DRD2 P14416 5/20 0.38
▸ DRD3 P35462 5/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ MET P08581 1/20 0.38
▸ FGFR1 P11362 1/20 0.37
▸ FGFR4 P22455 1/20 0.37
▸ CYP2C9 P11712 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22978560 0.89 GPR84 (0.41) CSF1RKITPDGFRAGPR84CYP3A4
SCHEMBL22988863 0.86 KIT (0.45) CSF1RKITPDGFRACYP3A4CYP2C19
SCHEMBL22988876 0.85 CSF1R (0.46) CSF1RKITPDGFRACYP3A4CYP2C19
SCHEMBL22988865 0.84 CSF1R (0.45) CSF1RKITPDGFRACYP3A4CYP2C19
SCHEMBL22988862 0.82 CSF1R (0.44) CSF1RKITPDGFRACYP3A4CYP2C19
SCHEMBL22978557 0.82 GPR84 (0.42) CSF1RKITGPR84CYP3A4CYP2C19
SCHEMBL22988825 0.79 CSF1R (0.44) CSF1RKITPDGFRA
SCHEMBL22988864 0.78 CSF1R (0.41) CSF1RKITPDGFRACYP3A4FGFR4
SCHEMBL27117863 0.74 CSF1R (0.45) CSF1RKITPDGFRA
SCHEMBL22988842 0.73 GPR84 (0.49) CSF1RKITPDGFRAGPR84CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018233526-A9 CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF 上海和誉生物医药科技有限公司 2021-02-18 — — WO disclosed
US-20160340361-A1 PIPERIDINE INHIBITORS OF JANUS KINASE 3 AUSPEX PHARMACEUTICALS, INC. 2016-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340361-A1 PIPERIDINE INHIBITORS OF JANUS KINASE 3 JAK2, JAK3, PAK3 CSF1R 1210/4885KIT 360/4885PDGFRA 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback